Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: Results from 2000-2001 and 2001-2002 TRUST studies in the United States

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 6, 2003, Pages 1790-1797

  Karlowsky, James A ^a   Thornsberry, Clyde ^b   Critchley, Ian A ^a   Jones, Mark E ^c   Evangelista, Alan T ^d   Noel, Gary J ^e,f   Sahm, Daniel F ^a  

^a Focus Technologies Incorporated   (United States)

^b Focus Technologies   (United States)

^c Focus Technologies   (Netherlands)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; LEVOFLOXACIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHILD; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; INFANT; LACTAMS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MORAXELLA (BRANHAMELLA) CATARRHALIS; OFLOXACIN; PNEUMOCOCCAL INFECTIONS; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UNITED STATES;

EID: 0038441385     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.6.1790-1797.2003     Document Type: Article

References (29)

1. Alghasham, A. A., and M. C. Nahata. 2000. Clinical use of fluoroquinolones in children. Ann. Pharmacother. 34:347-359.
2. Black, J., E. S. Moland, S. A. Chartrand, and K. S. Thomson. 2001. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 39:195-197.
3. Burkhardt, J. E., J. N. Walterspiel, and U. B. Schaad. 1997. Quinolone arthropathy in animals versus children. Clin. Infect. Dis. 25:1196-1204.
4. Chen, D. K., A. McGeer, J. C. De Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
5. Chiu, S. S., P. L. Ho, F. K. H. Chow, K. Y. Yuen, and Y. L. Lau. 2001. Nasopharyngeal carriage of antimicrobial-resistant Streptococccus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong. Antimicrob. Agents Chemother. 45:2765-2770.
6. Christ, W., T. Lehnert, and B. Uklbrich. 1988. Specific toxicologic aspects of the fluoroquinolones. Rev. Infect. Dis. 10:141-146.
7. Dagan, R. 1995. Fluoroquinolones in paediatrics-1995. Drugs 49(Suppl. 2):92-99.
8. Danisovicovà, A., T. Krcméryova, S. Belan, H. Kayserova, E. Kaiserova, I. Hruskovic, K. Orosova, S. Dluholucky, K. Galova, and E. Matheova. 1995. Magnetic resonance imaging in diagnosis of potential arthropathogenicity in children receiving quinolones. No evidence of quinolone-induced arthropathy. Drugs 49(Suppl. 2):492-494.
9. Doern, G. V., A. B. Brueggemann, G. Pierce, T. Hogan, H. P. Holley, and A. Rauch. 1996. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:2884-2886.
10. Doern, G. V., and The Alexander Project Collaborative Group. 1996. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-1993 Western Europe and USA collaborative surveillance study. J. Antimicrob. Chemother. 38(Suppl. A):59-69.
11. Doern, G. V., K. P. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffman, and A. B. Brueggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.
12. Felmingham, D., J. Washington, and The Alexander Project Group. 1999. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992-1996. J. Chemother. 11:5-21.
13. Ho, P. L., T. L. Que, D. N. Tsang, T. K. Ng, K. H. Chow, and W. H. Seto. 1999. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 43:1310-1313.
14. Jafri, H. S., and G. H. McCracken. 1999. Fluoroquinolones in pediatrics. Drugs 58(Suppl. 2):43-48.
15. Mandell, L. A., L. R. Peterson, R. Wise, D. Hooper, D. E. Low, U. B. Schadd, K. P. Klugman, and P. Couralin. 2002. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin. Infect. Dis. 35:721-727.
16. Morbidity and Mortality Wkly. Report. 2001. Resistance of Streptococcus pneumoniae to fluoroquinolones-United States, 1995-1999. Morb. Mortal. Wkly. Rep. 5:800-804.
17. Musher, D. M. 1995. Streptococcus pneumoniae, p. 1811-1826. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Philadelphia, Pa.
18. National Committee for Clinical Laboratory Standards. 2002. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. Approved standard, document M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. Sahm, D. F., J. A. Karlowsky, L. J. Kelly, I. A. Critchley, M. E. Jones, C. Thornsberry, Y. R. Mauriz, and J. Kahn. 2001. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob. Agents Chemother. 45:1037-1042.
21. Sahm, D. F., D. E. Peterson, I. A. Critchley, and C. Thornsberry. 2000. Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob. Agents Chemother. 44:2521-2524.
22. Schaad, U. B. 1993. Use of fluoroquinolones in pediatrics. Drugs 45(Suppl. 3):37-41.
23. Schaad, U. B. 1994. Use of the new quinolones in pediatrics. Isr. J. Med. Sci. 30:463-468.
24. Thomson, K. S., S. A. Chartrand, C. C. Sanders, and S. L. Block. 1997. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:478-480.
25. Thornsberry, C., M. E. Jones, M. L. Hickey, Y. Mauriz, J. Kahn, and D. F. Sahm. 1999. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 199-1998. J. Antimicrob. Chemother. 44:749-759.
26. Tomeh, M. O., S. E. Starr, J. E. McGowan, Jr., P. M. Terry, and A. J. Nahamias. 1974. Ampicillin-resistant Haemophilus influenzae type B infection. J. Am. Med. Assoc. 229:295-297.
27. Warren, R. W. 1997. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr. Infect. Dis. J. 16:118-122.
28. Yagupsky, P., O. Katz, N. Peled, and R. Dagan. 2001. In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media. Chemotherapy 47:354-358.
29. Yee, C. L., C. Duffy, P. G. Gerbino, S. Stryker, and G. J. Noel. 2002. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr. Infect. Dis. J. 21:525-529.